Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Afatinib gevolgd door osimertinib bij EGFR-gemuteerd NSCLC
okt 2018 | Longoncologie